Advertisement: TTP Killer 50
16 July, 2018 - 11:46 By Kate Sweeney

Cancer models platform eliminating barriers for drug discovery researchers

Cambridge-based Repositive has introduced new features to its Cancer Models Platform, responding to feedback from a growing user base. 

The platform provides oncology researchers with an holistic, searchable, comparable view of existing cancer models, while providing Contract Research Organisations with a tool to market, manage and analyse their models.

Repositive initially created its PDX model sharing platform in 2017 and extended its scope to become the broader Cancer Models Platform. Repositive will demonstrate the new functionalities at the Tumor Models Conference in Boston from July 16–18.

Chris Taylor, product manager at Repositive, said: “We have responded to feedback from early adopters, expanding the platform to incorporate a wider range of translational cancer models and related services, but also providing standardised metadata and molecular characteristics. This enables us to facilitate enhanced search and effective comparison of all available models – something which is not possible when researchers try to compare model data from other CROs using different metadata parameters.

“This challenge is one that academics have begun to resolve for publicly available data and one that we, at Repositive, have taken on in order to create a consensus for industry, too. 

“This has the potential to revolutionise the process of discovering and accessing the best cancer models for research projects and, as our ambition is to enable better and faster discovery of treatments and cures through technological innovation, we were only too ready to take on this challenge.” 

Benefits for oncology researchers include easy access to a greater number and diversity of models. 

The search function is precise down to the specific genomic characteristics required, and the platform’s security and IP protection enables researchers to locate models without jeopardising the confidentiality of details about current or future projects. 

Fiona Nielsen, founder and CEO of Repositive, said: “Our Cancer Models Platform eliminates one of the greatest barriers researchers face in discovering the best cancer models to make progress in drug discovery. 

“We are continually developing the platform based on feedback from our partners and we look forward to demonstrating its potential to visitors at the Tumor Models Conference in Boston, whilst gathering further information to help us to continue developing its usability.

“During our time in the US, we are also hosting a networking event to bring together oncology researchers from across academia, biopharma and biotech, to discuss model selection for immuno-oncology and combination therapies.”

• PHOTOGRAPH: Repositive team members - Robert Thong, Adam Wells, Fiona Nielsen and Adrian Alexa. Image by Matthew Power Photography

Newsletter Subscription

Stay informed of the latest news and features